Lilly, Ligand Extend R&D Collaboration to Discover and Develop Novel Drugs for Metabolic Diseases
Alliance Partners Provide Development Update on Portfolio of Potential Drugs for Diabetes, Cardiovascular Disorders and Obesity
15-Apr-2002 -
Eli Lilly and Company and Ligand Pharmaceuticals Incorporated will extend until November 2003 their research collaboration focused on discovering novel drugs for type II diabetes, cardiovascular disorders and obesity, the companies announced today. Lilly retains rights to extend the collaboration ...
cardiovascular diseases
clinical trials
diabetes
+10